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Abstract
Background: The body mass index (BMI) is the most commonly used marker for evaluating obesity related risks,
however, central obesity measures have been proposed to be more informative. Lipid accumulation product (LAP)
is an alternative continuous index of lipid accumulation. We sought in this study to assess if LAP can outperform
BMI, waist-to-height-ratio (WHtR), or waist-to-hip-ratio (WHpR) in predicting incident cardiovascular disease (CVD) or
all-cause mortality.
Results: Among participants of Tehran Lipid and Glucose Study, 6,751 participants (2,964 men), aged ≥ 30 years,
were followed for a median of 8.6 years. We observed 274 deaths (men: 168) and 447 CVD events (men: 257).
Levels of common CVD risk factors significantly increased across LAP quartiles. Mortality rates did not differ by LAP
quartiles. Among participants free of CVD at baseline [6331 (2,741 men)], CVD incident rates per 1000 person
increased in a stepwise fashion with increasing LAP quartile values in both men (from 6.9 to 17.0) and women
(from 1.3 to 13.0), (Ps < 0.001).
Among women, a 1-SD increment in log-LAP conferred a 41% increased risk for CVD (HR 1.41, 95% CIs 1.02-1.96).
Among men, however, LAP was not observed to be independently associated with increased risk of CVD; except in
a sub-group of men assigned to the lifestyle modification interventions, where, LAP predicted CVD risk.
After adjustment with CVD risk factors LAP turned to be inversely associated with risk of all-cause mortality (HR,
men 0.74, 95% CIs 0.61-0.90; women, 0.94 95% CIs 0.74-1.20).
Among women, magnitude of increased risk of CVD due to LAP was not different from those of anthropometric
measures. Among men, however, WHpR was observed to be more strongly associated with increased risk of CVD
than was LAP.
Among neither men nor women were the predictive performances (discrimination, calibration, goodness-of-fit) of
the LAP better than those of different anthropometric measures were.
Conclusions: If LAP is to be used for predicting CVD, it might not be superior to WHtR or WHpR.
Background
In his seminal 1988 Banting award lecture, Reaven
introduced insulin resistance as a fundamental “disor-
der” associated with a set of metabolic abnormalities
contributed to the development of cardiovascular
disease (CVD) [1]. Large prospective studies [2-7] have
shown that insulin resistance is a predictor of coronary
artery disease (CAD). It is also relevant to mention that
as Reaven found insulin resistant individuals who were
not obese, he did not include obesity as a feature of the
insulin resistance syndrome. Since then, a plethora of
studies increasingly recognized insulin resistance,
assessed by various methods, to be underlying factor
associated with clustering atherogenic abnormalities [8].
Measuring indices of insulin sensitivity could not be
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tions, thus, have proposed the “metabolic syndrome
(MetS),” a constellation of simple clinical parameters
with cut-off values, to find individuals who would prob-
ably be insulin resistant [9-14]. Since then, a clinical
diagnosis of the MetS was frequently shown to be asso-
ciated with an increased risk of CVD [8]. It is well-docu-
mented that obesity is associated with insulin resistance
[8]. However, obesity is remarkably heterogeneous as
some obese patients are insulin sensitive whereas others
are insulin resistant [15]. With remarkable heterogeneity
of obesity in mind, measuring an index of abdominal
adiposity such as the waist circumference (WC) is clini-
cally relevant, since among obese individuals, there is a
subgroup of abdominally obese patients who are more
likely to be insulin resistant [8]. With the introduction
of the MetS, the abdominal obesity was recognized as a
clinically measurable (although imperfect) entity
[8,16-18]. “An Increased WC, however, does not always
mean high-risk visceral obesity [8].” WC cannot distin-
guish visceral adiposity, an important correlate of
metabolic abnormalities, from the amount of subcuta-
neous abdominal fat. On the other hand, as an alterna-
tive to MetS, a more fundamental syndromic concept
has been introduced. It might be defined by the limited
capacity of the human body to buffer and dispose of
lipid fuels. During periods of lipid excess, along with
expansion of visceral adipocytes, the blood concentra-
tions of certain lipids would become chronically ele-
vated. This state, referred to as “lipid over-
accumulation [19] could lead to ectopic deposition of
lipids in non-adipose tissues, where insulin resistance
and other metabolic dysfunctions would arise [20-22].
Some clinicians therefore used triglyceride (TGs) along
with WC (hypertriglyceridemic waist) to find obese
patients with abdominal obesity [23]. Lipid accumula-
tion product (LAP), based on a combination of WC
and the fasting concentration of circulating TG has
recently been introduced by Kahn et al [20]. WC and
TGs are each continuously associated with insulin
resistance and cardiovascular risk [8]. Against hypertri-
glyceridemic waist that serve as a dichotomous risk
marker [22,23], the LAP was developed to express a
continuous risk function [21].
LAP has been shown to predict incident diabetes [24]
and all cause mortality [25]. Whether increased LAP
confers an excess risk of CVD or not has not directly
been addressed. Less is known concerning the perfor-
mance of LAP as compared to the measures of general
and abdominal adiposity. Our primary focus in this
study, therefore, was to assess if LAP can outperform
BMI, waist-to-height ratio (WHtR), or waist-to-hip ratio
(WHpR) in predicting incident CVD.
Methods
Study population
Detailed descriptions of the Tehran lipid and glucose
study (TLGS) have been reported elsewhere [26]; in
brief, the TLGS is a large scale, long term, community-
based prospective study performed on a representative
sample of residents of district No. 13 of Tehran, capital
of Iran. Age and sex distributions of the population in
the district were representative of the overall population
of Tehran at the time of the baseline examination. A
total of 27,340 residents were invited by telephone call,
of which 15,005 residents (54.9%) aged ≥3 years partici-
pated. The TLGS has two major components: a cross-
sectional prevalence study of non-communicable disease
and associated risk factors, implemented between March
1999 and December 2001, and a prospective follow-up
study. Data collection is ongoing, designed to continue
for at least 20 years, at 3-year intervals. Participants
were categorized into the cohort (n = 9375) and inter-
vention groups (n = 5630), the latter to be educated for
implementation of life style modifications. For the cur-
rent study, of those aged ≥30 (n = 8,071), we selected
those who participated in the follow-up study until 10
March 2009 (n = 7,133). After exclusions (382 missing
data), 6,751 (2,964 men) participants remained eligible
(response rate 95%). At the time of this study, the med-
ian follow up time was 8.7 years. Participants were pro-
vided with information regarding the result of their
examinations and were given suitable advice. Informed
written consent was obtained from all participants and
the ethical committee of the Research Institute for
Endocrine Sciences approved this study.
Clinical and laboratory measurements
A trained interviewer collected information using a pre-
tested questionnaire. The information obtained included
demographic data, family history of premature CVD,
past medical history of CVD, and smoking status.
Weight was measured, with subjects minimally clothed
without shoes, using digital scales (Seca 707: range 0.1-
150 kg) and recorded to the nearest 100 g. Height was
measured in a standing position without shoes, using
tape meter while shoulders were in a normal alignment.
Waist circumference (WC) was measured at the umbili-
cal level and that of the hip at the maximum level over
light clothing, using an unstretched tape meter, without
any pressure to body surface and measurements were
recorded to the nearest 0.1 cm [27]. BMI (kg.m
-2)w a s
calculated as weight (kg) divided by square of the height
(m
2). WHpR was calculated as WC (cm) divided by hip
circumference (cm) and WHtR was calculated as WC
divided by height (cm). After a 15-minute rest in the sit-
ting position, two measurements of blood pressure were
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sphygmomanometer (calibrated by the Iranian Institute
of Standards and Industrial Researches); the mean of the
two measurements was considered as the participant’s
blood pressure.
A blood sample was drawn between 7:00 and 9:00 AM
from all study participants, after 12 to 14 hours over-
night fasting. All the blood analyses were undertaken at
the TLGS research laboratory on the day of blood col-
lection. Plasma glucose was measured using an enzy-
matic colorimetric method with glucose oxidase. Fasting
plasma glucose (FPG) measurement was performed for
all participants, and the standard 2-hour post-challenge
plasma glucose (2h-PCPG) test for those not on glu-
cose-lowering drugs. Total cholesterol (TC) was assayed,
using the enzymatic colorimetric method with choles-
terol esterase and cholesterol oxidase. High-density lipo-
protein cholesterol (HDL-C) was measured after
precipitation of the apolipoprotein B containing lipopro-
teins with phosphotungistic acid. TGs were assayed
using enzymatic colorimetric assay with glycerol phos-
phate oxidase. Analyses were performed using Pars
Azmon kits (Pars Azmon Inc., Tehran, Iran) and a
Selectra 2 auto-analyzer (Vital Scientific, Spankeren,
Netherlands). All samples were analyzed when internal
quality control met the acceptable criteria. The intra
and inter-assay coefficients of variation were both <2.2%
for plasma glucose, and 0.5 and 2% for TC, respectively
[26].
Outcome measurements
Details of cardiovascular outcomes have been published
elsewhere [28]. In this ongoing study every TLGS’ parti-
cipant is followed up for any medical event during the
previous year, by telephone. They are questioned by a
trained nurse regarding any medical conditions or
whether a related event have occurred, a trained physi-
cian collects complementary data during a home visit
and/or a visit to the respective hospital to collect data
from the participants medical files. In the case of mor-
tality, data are collected from the hospital or the death
certificate by an authorized local physician. Collected
data are evaluated by an outcome committee consisting
of a principal investigator, an internist, an endocrinolo-
gist, a cardiologist, an epidemiologist, and the physician
who collects the outcome data. Other experts are invited
for evaluation of non-communicable disorders, as
needed. A specific outcome for each event is assigned
according to International Statistical Classification of
Diseases and Related Health Problems criteria, 10th
Revision, and American Heart Association classification
for cardiovascular events [26,29,30]. Coronary heart dis-
ease (CHD) includes cases of definite myocardial infarc-
tion (MI) diagnosed by electrocardiogram (ECG) and
biomarkers, probable MI (positive ECG findings plus
cardiac symptoms or signs and biomarkers showing
negative or equivocal results), unstable angina pectoris
(new cardiac symptoms or changing symptom patterns
and positive ECG findings with normal biomarkers),
angiographic proven CHD and CHD death. CVD is spe-
cified as a composite measure of any CHD events,
stroke, or cerebrovascular death.
Definition of terms
Lipid accumulation product (LAP) is an alternative con-
tinuous index of lipid accumulation, which is computed
from WC (cm) and TGs (mmol.l
-1): (WC-65) ×TG
(men) and (WC-58) ×TG (women). A previous history
of CVD reflected any prior diagnosis of CVD by a physi-
cian. The family history of CVD was obtained by asking
participants whether any member in their immediate
family (first-degree relatives) had experienced a fatal or
nonfatal MI, stroke or sudden cardiac arrest. The event
was considered premature if it occurred before the age
of 55 years in male relatives and before 65 in female
relatives [31]. Current smoker was defined as a person
who smokes cigarettes daily or occasionally. The diagno-
sis of hypertension was made in participants who self
reported antihypertensive drug usage or in those with
the average of the two diastolic blood pressure measure-
ments was ≥ 90 mmHg or when the average of the two
systolic blood pressure measurements was ≥ 140 mm
Hg [32]. High cholesterol was ascertained in those with
total cholesterol ≥ 5.2 mmol.l
-1, high TGs in those with
TGs ≥ 1.7 mmol.l
-1, and low HDL-C in men with HDL-
C < 1.03 mmol.l
-1l and in women with HDL-C <1.29
mmol.l
-1 [33]. Participants using oral hypoglycemic
agents or insulin were considered as having diabetes.
Diabetes was also ascertained in participants with FPG
≥7.0 mmol.l
-1 or 2h-PCPG ≥11.1 mmol.l
-1 [34]. Non-
HDL- C was calculated by subtracting HDL-C from
total cholesterol.
Statistics analysis
Findings on covariate variables are expressed as means
(SD) or percentages for continuously distributed and
categorical variables, respectively. We tested for trends
across LAP quartiles by using the median in each quar-
tile as a predictor, separately for each sex. The General
Linear Model was developed for continuous variables,
and the Cox proportional hazards regression model was
used for incidence rates. Models were adjusted for age.
For each participant, free of CVD at baseline, the
baseline 10-year risk of CVD was calculated using the
Framingham’s “general CVD risk prediction algorithm
[35].” We divided the study sample into those with high
and low global risk of CVD. Then, in each sub-group,
Kaplan-Meier survival curves were plotted to
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quartiles. The Log-Rank test was performed to examine
the significance of trends across LAP quartiles.
When CVD was considered as outcome another 521
prevalent CVD cases were also excluded from the analy-
sis leaving a final sample of 6,331 participants (2741
men). In the analysis of CVD outcome, LAP, BMI,
WHpR, and WHtR were assessed using Cox propor-
tional hazards regression analyses. Survival time was the
time from start of the follow-up period to the date of
the first incident, CVD event, or death due to any cause
(failure). The censoring time of an individual was the
time from entry into the study to loss to follow-up or
the end of the study, whichever happened first. Cen-
sored observation meant the subject either refused to
participate further in the study (lost to follow-up), died,
when death was not the study outcome (competing
risk) or continued until the study was ended (adminis-
trative censoring). Valid comparison of hazards ratios
(HRs) for different continuous measures requires that
the units of both variables to be comparable. We, thus,
estimated sex-specific hazard ratios (HRs), with 95%
confidence intervals (CI) for follow-up events for an
one SD increment in natural log-transformed LAP and
each respective anthropometric parameter. HRs were
adjusted for age, smoking, systolic blood pressure,
family history of premature CVD, diabetes, antihyper-
tensive drug usage, HDL and non-HDL cholesterol,
FPG, and 2h-PCPG [31], plus the TLGS intervention
measures.
We also examined if the effects of LAP on incident
CVD or all-cause mortality has been modified by differ-
ent levels of risk (<20 vs. ≥20%) [35] or life style modifi-
cation measures. We introduced interaction terms
between LAP and global CVD risk levels and LAP and
intervention assignment status.
Wald tests of the linear hypotheses concerning the
Cox regression models coefficients (paired homogeneity
test) were performed to test the null hypotheses that the
hazard ratios (effect size) for LAP were equal to those
for anthropometric measures.
We compared predictive performance of the LAP with
those of the studied anthropometric variables with
respect to discrimination, calibration, and goodness-of-
fit.
Discrimination is the ability of a prediction model to
separate those who develop diabetes events from those
who do not and is quantified by the C statistic [36]. In
the survival analysis, C statistic [37] measures the prob-
ability that a randomly selected person who developed
an event, at the certain specific time has a higher risk
score than a randomly selected person who did not
develop an event during the same, specific follow-up
interval [38].
Calibration, as it is phrased in reference [39] describes
how closely predicted probabilities agree numerically
with actual outcomes [40,41]. A test very similar to the
Hosmer-Lemeshow test has been proposed by Grønnsby
and Borgan, which is based on sum of martingale resi-
duals within groups that have been developed by parti-
tioning the data based on the estimated risk score (x’b)
[42,43]. Following May and Hosmer we calculated the
test statistic using score test (c
2) for the inclusion of G-
1 reference cell design variables [41,44,45].
How effectively a model describes the outcome vari-
able is referred to as its goodness-of-fit. Akaike infor-
mation criterion (AIC) was used as a measure of
model fit and informativeness indicating whether the
addition of new factors to a base model provides better
risk prediction than the base model alone, provided
that all of the same individuals are being assessed by
both models [46]. When estimating model parameters
using maximum likelihood estimation, it is possible to
increase the likelihood by adding parameters, which
may result in over-fitting. The Bayesian information
criterion (BIC) resolves this problem by introducing a
penalty term for the number of parameters in the
model. It is very closely related to the AIC. In BIC, the
penalty for additional parameters is stronger than that
of the AIC [47].
Because BMI, WHpR, WHtR, and LAP were highly
correlated, we assessed collinearity between these vari-
ables using condition indices and variance inflation fac-
tor (VIF). Condition indices >30 or VIFs >10 warrant
caution [48].
We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of human
volunteers were followed during this research. Informed
written consent was obtained from all participants and
the Ethical Committee of Research Institute for Endo-
crine Sciences approved this study.
We set the statistical significance level at a two-tailed
type I error of 0.05. All statistical analyses were per-
formed using STATA 10.0.
Result
During follow up (men: 24,209 person-year; women:
31,454 person-year), 274 deaths (men: 168; women:
106) and 447 CVD events (men: 257; women: 190)
occurred. The major causes of death were fatal CVD
events (36.6%), cancers (11.7%), diabetes complications
(4.7%), trauma (4.4%), and infectious disease (3.3).
CVD incident rates among participants who were
assigned to life style modification measures (men: 10.6,
95% CIs 8.7-13.1; women: 6.2, 95% CIs 4.9-7.8) was
not different from those who were not (men: 12.4, 95%
CIs 10.6-14.4; women: 6.6, 95% CIs 5.5-7.9). Mortality
rates were also the same in the intervention group
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4.8) and the cohort (men: 7.4, 95% CIs 6.1-8.9; women,
3.3, CIs 2.5-4.2) (all Ps > 0.3). The prevalence of high
TG, high total cholesterol, low HDL-C, hypertension,
diabetes, family history of CVD, and prevalent CVD
were 56.6, 58.3, 35.3, 39.0, 16.4, 8.0, and 7.5%, among
men and 52.7, 66.1, 25.5, 39.6, 17.7, 12.1, and 5.2%
among women, respectively.
A ss h o w ni nT a b l e1a n d2 ,l e v e l so fc o m m o nC V D
risk factors significantly increases across LAP quartiles,
except for family history of premature CVD among men
and smoking among both sexes. CVD incident rates per
1000 person increased in a stepwise fashion with
increasing LAP quartile values in both men (from 6.9 to
17.0) and women (from 1.3 to 13.0), (P for trends
<0.001). Mortality rates, however, remained unchanged
across LAP quartiles.
Table 3 presents the contribution of LAP to the risk
of CVD, independent of other CVD risk factors, sepa-
rately for men and women.
Among women, a 1-SD (0.81) increment in log LAP
conferred a 41% increased risk for CVD (HR 1.41, 95%
CI 1.02-1.96). Among men, however, LAP was not
observed to be independently associated with increased
risk of CVD. Multivariate adjusted hazard ratios for a 1-
SD increment in WC for CVD and all-cause mortality
among men were 1.18 (95% CIs 1.01-1.39, P = 0.036)
and 0.90 (95% CIs 0.72-0.1.12, P = 0.348), respectively;
the corresponding figures among women were 1.24
(95% CIs 1.03-1.49, P = 0.021) and 0.84 (95% CIs 0.65-
1.09, P = 0.197). Hazard ratios for a 1-SD increment in
TG for CVD and all-cause mortality among men were
1.00 (95% CIs 0.88-1.1.41, P = 0.953) and 0.75 (95% CIs
0.56-1.00, P = 0.055), respectively; the corresponding
Table 1 Baseline characteristics across quartiles of lipid accumulation product among men
Q1 (cm.mmol.l
-1)
<2288
Q2 (cm.mmol.l
-1) 2289-
4186
Q3 (cm.mmol.l
-1) 4192-
6900
Q4 (cm.mmol.l
-1) 6912-
57000
P for
trends
†
Number of participants* 741 741 742 740
Age (years) 48.1(14.4) 49.1(13.6) 50.7(13.0) 49.2(12.5)
SBP (mmHg) 117.2(19.8) 122.0(19.3) 126.8(20.9) 127.6(19.0) <0.001
DBP (mmHg) 73.9(11.5) 77.9(10.6) 81.1(11.2) 82.0(11.2) <0.001
MAP (mmHg) 88.3(12.8) 92.6(12.2) 96.4(13.1) 97.2(12.6) <0.001
Pulse pressure (mmHg) 43.3(16.1) 44.1(15.0) 45.7(16.0) 45.5(14.1) <0.001
Pulse (beat per minute) 73.1(10.0) 73.6(9.9) 75.1(9.5) 76.3(9.7) <0.001
BMI (kg.m
-2) 22.4(2.8) 25.7(2.7) 27.6(2.8) 29.3(3.5) <0.001
Waist-to-hip ratio (%) 86.2(5.5) 92.9(5.2) 95.9(5.3) 98.3(5.6) <0.001
Waist-to-height ratio (%) 46.5(4.6) 52.9(4.4) 56.0(4.4) 58.8(5.2) <0.001
Lipid accumulation product 11.4(2.2) 35.9(1.2) 60.3(1.2) 117.9(1.4) <0.001
Triglycerides (mmol.l
-1) 1.1(1.4) 1.6(1.5) 2.1(1.3) 3.5(1.5) <0.001
Total cholesterol (mmol.l
-1) 4.9(1.0) 5.3(0.9) 5.6(1.0) 6.0(1.2) <0.001
Non-HDL-C (mmol.l
-1) 3.8(0.9) 4.3(0.9) 4.6(0.9) 5.2(1.1) <0.001
HDL-C (mmol.l
-1) 1.1(0.3) 1.0(0.2) 1.0(0.2) 0.9(0.2) <0.001
FPG (mmol.l
-1) 5.2(1.4) 5.4(1.5) 5.6(1.7) 6.1(2.3) <0.001
2h-PCPG (mmol.l
-1) 5.5(2.6) 6.4(3.2) 6.9(3.5) 8.0(4.2) <0.001
Assignment to intervention
(%)
288 (38.9) 281 (37.9) 275 (37.1) 305 (41.2) 0.347
Diabetes 59 (8.0) 76 (10.3) 146 (19.7) 205 (27.7) <0.001
Hypertension 253 (34.1) 366 (49.4) 462 (62.3) 476 (64.3) <0.001
Smoking 253 (34.1) 202 (27.3) 176 (23.7) 208 (28.1) 0.001
Family history of premature
CVD
49 (6.6) 58 (7.8) 70 (4.9) 61 (8.2) 0.223
Incident** CHD (95% CIs) 5.3(3.8-7.6) 8.6(6.5-11.5) 11.2(8.7-14.4) 15.0(12.1-18.6) <0.001
Incident** CVD (95% CIs) 6.9(5.1-9.4) 10.1(7.8-13.2) 13.2(10.4-16.6) 17.0(13.8-20.8) <0.001
Mortality** rate (95% CIs) 8.3(6.3-11.0) 7.6(5.7-10.2) 6.1(4.4-8.4) 5.8(4.2-8.1) 0.134
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high density lipoprotein cholesterol; MAP, mean arterial pressure 2h-
PCPG, 2-hour post-challenge plasma glucose; SBP, systolic blood pressure;.
Continuous variables are represented as mean (standard deviation) except for triglycerides and lipid accumulation products that are represented as geometric
mean (standard deviation of geometric mean). Categorical variables are represented as frequency (percent). Confidence intervals have been provided for incident
rates.
**Per 1000 person per year
† P-values were calculated using general linear models, for continuous variables and Cox proportional hazards regression models for incidence rates. Models
were sex-specific and age-adjusted.
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0.834) and 1.26 (95% CIs 0.88-1.81, P = 0.206),
respectively.
We failed to demonstrate any increased risk of all-
cause mortality owing to LAP (Table 4). In fact, after
adjustment with CVD risk factors LAP turned to be
inversely associated with risk of all-cause mortality. This
association, however, was statistically significant among
men (HR 0.74, 95% CIs 0.61-0.90) but not among
women (HRs 0.94 95% CIs 0.74-1.20).
F i g u r e s1 ,2 ,3 ,4 ,5 ,6 ,7 ,a n d8r e p r e s e n tt h es e x - s p e -
cific Kaplan-Meier curves for CVD and all-cause mortal-
ity, across LAP quartiles in the two sub-groups defined
by baseline global CVD risk ≥ 20% and < 20%. Among
women with global CVD risk less than 20%, the prob-
ability of remaining free of CVD decreased in stepwise
fashion across LAP quartiles. Such a trend was not
observed among women with global CVD risk of 20% or
more. In the contrary, in men it was among those with
global CVD risk ≥20% that the probability of remaining
free of CVD across decreased across LAP quartiles.
Kaplan-Meier survival curves plotted for all-cause mor-
tality showed that survival prognosis improved in step-
wise fashion across LAP quartiles among men,
regardless of their baseline global CVD risk. Among
women survival prognosis did not differ by LAP
quartiles.
In multivariate-adjusted Cox proportional hazard
regression models LAP predicted incident CVD only
among women with global CVD risk less than 20%,
while it did not predict all-cause mortality in any of
sub-groups (Table 5).
When we introduced interaction terms between inter-
vention assignment status and LAP to the models,
Table 2 Baseline characteristics across quartilesof lipid accumulation product among women
Q1 (cm.mmol.l
-1)
<2752
Q2 (cm.mmol.l
-1) 2755-
5040
Q3 (cm.mmol.l
-1) 5043-
8265
Q4 (cm.mmol.l
-1) 8268-
54948
P for
trends
†
Number of participants* 947 954 939 947
Age (years) 40.6(10.4) 46.5(11.7) 49.9(11.6) 52.1(10.8)
SBP (mmHg) 112.7(15.7) 120.9(18.7) 127.7(21.8) 133.2(21.9) <0.001
DBP (mmHg) 74.6(9.4) 78.3(10.1) 82.0(10.7) 84.3(10.8) <0.001
MAP (mmHg) 87.3(10.5) 92.5(11.8) 97.2(13.1) 100.6(13.2) <0.001
Pulse pressure (mmHg) 38.1(11.8) 42.5(14.5) 45.7(16.8) 48.9(16.8) <0.001
Pulse (beat per minute) 80.9(11.9) 81.0(12.1) 80.8(11.9) 81.7(12.0) <0.012
BMI (kg.m
-2) 24.7(3.5) 27.9(3.6) 29.9(4.2) 31.7(4.5) <0.001
Waist-to-hip ratio (%) 78.5(6.5) 85.3(6.6) 88.5(6.8) 92.2(7.0) <0.001
Waist-to-height ratio (%) 49.9(5.2) 57.1(5.4) 61.3(5.9) 65.4(6.2) <0.001
Lipid accumulation product 17.8(1.6) 42.9(1.2 73.0(1.2) 135.6(1.4) <0.001
Triglycerides (mmol.l
-1) 1.0(1.4) 1.4(1.3) 2.0(1.3) 3.2(1.4) <0.001
Total cholesterol (mmol.l
-1) 5.0(1.0) 5.5(1.0) 6.0(1.1) 6.5(1.3) <0.001
Non-HDL-C (mmol.l
-1) 3.8(0.9) 4.3(1.0) 4.9(1.1) 5.5(1.3) <0.001
HDL-C (mmol.l
-1) 1.3(0.3) 1.2(0.3) 1.1(0.3) 1.0(0.3) <0.001
FPG (mmol.l
-1) 5.0(1.3) 5.3(1.6) 5.9(2.3) 6.5(2.8) <0.001
2h-PCPG (mmol.l
-1) 5.8(1.8) 6.5(2.3) 7.4(3.2) 8.7(4.2) <0.001
Assignment to intervention
(%)
362 (38.2) 387 (40.6) 363 (38.7) 365 (38.5) 0.657
Diabetes 46 (4.9) 104 (10.9) 197 (21.0) 322 (34.0) <0.001
Hypertension 288 (28.3) 472 (42.5) 585 (62.3) 699 (73.8) <0.001
Smoking 44 (4.7) 37 (3.9) 30 (3.2) 28 (3.0) 0.748
Family history of premature
CVD
92 (9.7) 107 (11.2) 129 (13.7) 131 (13.8) <0.010
Incident** CHD (95% CIs) 1.1 (0.6-2.2) 3.6 (2.4-5.2) 7.4 (5.7-9.7) 11.2 (8.9-14.0) <0.001
Incident** CVD (95% CIs) 1.3 (0.7-2.4) 4.1 (2.9-5.8) 8.3 (6.4-10.7) 13.0 (10.5-16.0) <0.001
Mortality** rate (95% CIs) 2.4(1.5-3.7) 2.5(1.6-3.9) 4.1(2.9-5.8) 4.5(3.3-6.3) 0.673
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high density lipoprotein cholesterol; MAP, mean arterial pressure 2h-
PCPG, 2-hour post-challenge plasma glucose; SBP, systolic blood pressure;.
Continuous variables are represented as mean (standard deviation) except for triglycerides and lipid accumulation products that are represented as geometric
mean (standard deviation of geometric mean). Categorical variables are represented as frequency (percent). Confidence intervals have been provided for incident
rates.
**Per 1000 person per year
† P-values were calculated using general linear models, for continuous variables and Cox proportional hazards regression models for incidence rates. Models
were sex-specific and age-adjusted.
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Page 6 of 13among both men and women the results remained
essentially unchanged (Ps for interactions >0.07). None-
theless, we examined the effects of LAP on risk of CVD
and all-cause mortality separately for those who were
assigned to the life style modification measures and
those who were not (Tables 5). The finding of interest
was that LAP conferred a 58% increase in the risk of
CVD among men who were assigned to the life style
modification interventions (HR 1.58, 95% CIs 1.11-2.26).
Among women CVD risk conferred by LAP for both
sub-groups were similar to that of whole sample,
though, no longer statistically significant. It may be due
to the broadened 95% CIs and decreased statistical
power.
Relative importance of LAP has been compared with
those of anthropometric measures in Table 6. Among
women, the magnitude of increased risk of CVD due to
LAP was not different from those of anthropometric
measures. Among men, however, WHpR was observed
to be more strongly associated with increased risk of
CVD than was LAP.
Table 6 represents the different measures of predictive
performance of models incorporating LAP, BMI,
WHpR, and WHtR, each at a time. Models
Table 3 Contribution of LAP to the risk of CVD, independent of common CVD risk factors among men and women
Men Women
HR* (95% CIs) P-value HR* (95% CIs) P-value
Age (years) 1.05 (1.04-1.06) <0.001 1.06 (1.04-1.08) <0.001
Smoking 1.86 (1.37-2.51) <0.001 2.97 (1.36-6.47) 0.006
Premature history of CVD 1.47 (0.94-2.32) 0.094 1.60 (1.01-2.52) 0.044
Diabetes 1.30 (0.81-2.08) 0.271 1.95 (1.13-3.35) 0.017
Antihypertensive drug use 1.42 (0.97-2.08) 0.068 2.04 (1.40-2.98) <0.001
Systolic blood pressure (mmHg) 1.40 (1.24-1.58) 0.000 1.23 (1.04-1.46) 0.014
Intervention 0.76 (0.57-1.01) 0.059 0.96 (0.67-1.38) 0.842
Non-HDL-C (mmol.l
-1) 1.34 (1.15-1.56) <0.001 1.25 (1.05-1.50) 0.014
HDL-C (mmol.l
-1) 0.81 (0.67-0.97) 0.022 1.06 (0.88-1.28) 0.547
FPG (mmol.l
-1) 1.29 (0.97-1.71) 0.075 0.81 (0.60-1.09) 0.169
2h-PCPG (mmol.l
-1) 0.97 (0.79-1.20) 0.800 1.10 (0.90-1.35) 0.342
Ln LAP (cm.mmol.l
-1) 1.06 (0.89-1.26) 0.535 1.41 (1.02-1.96) 0.038
* For one SD increment in each continuous predictor, obtained from multivariate Cox proportional hazards regression model adjusted for age, smoking, systolic
blood pressure, family history of premature CVD, diabetes, antihypertensive drug usage, HDL and non-HDL cholesterol, FPG, and 2h-PCPG , plus the TLGS
intervention measures.
CVD, cardiovascular disease; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; Ln,
naturally logarithmically transformed; 2h-PCPG, 2-hour post-challenge plasma glucose;
Table 4 Contribution of LAP to the risk of all-cause mortality, independent of common CVD risk factors among men
and women
Men Women
HR* (95% CIs) P-value HR* (95% CIs) P-value
Age (years) 1.09 (1.07-1.11) <0.001 1.14 (1.11-1.18) <0.001
Smoking 2.01 (1.32-3.04) 0.001 2.27 (0.69-7.50) 0.179
Premature history of CVD 0.58 (0.23-1.41) 0.228 1.16 (0.55-2.47) 0.692
Diabetes 1.52 (0.86-2.69) 0.151 1.30 (0.51-3.34) 0.579
Antihypertensive drug use 1.97 (1.31-2.98) 0.001 1.59 (0.92-2.74) 0.094
Systolic blood pressure (mmHg) 1.20 (1.03-1.40) 0.022 1.03 (0.80-1.32) 0.822
Intervention 0.69 (0.47-1.02) 0.061 1.10 (0.66-1.84) 0.708
Non-HDL-C (mmol.l
-1) 0.94 (0.75-1.18) 0.595 0.86 (0.64-1.15) 0.295
HDL-C (mmol.l
-1) 0.87 (0.69-1.08) 0.197 0.93 (0.71-1.22) 0.582
FPG (mmol.l
-1) 1.19 (0.82-1.72) 0.366 0.67 (0.34-1.32) 0.253
2h-PCPG (mmol.l
-1) 1.02 (0.79-1.31) 0.892 1.18 (0.86-1.63) 0.310
Ln LAP (cm.mmol.l
-1) 0.74 (0.61-0.90) 0.003 0.88 (0.60-1.30) 0.530
* For one SD increment in each continuous predictor, obtained from multivariate Cox proportional hazards regression model adjusted for age, smoking, systolic
blood pressure, family history of premature CVD, diabetes, antihypertensive drug usage, HDL and non-HDL cholesterol, FPG, and 2h-PCPG , plus the TLGS
intervention measures.
CVD, cardiovascular disease; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; Ln,
naturally logarithmically transformed; 2h-PCPG, 2-hour post-challenge plasma glucose;
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sures generally better fit the data among women (AICs
1872-1878, BIC 1945-1951) than among men (AICs
3128-3134, BIC 3198-3204). The discrimination capaci-
ties of the models were also higher among women (C
statistics 0.846-0.849) than among men (C statistics
0.785-0.788). The model-based estimated risk of CVD
again better agreed with observed risk among women
(Hosmer-Lemeshow c
2 11.9-12.8) than among men
(Hosmer-Lemeshow c
2 18.0-21.6). Among neither men
nor women were the predictive performances of the
LAP better than those of different anthropometric mea-
sures were.
Discussion
For the first time, using data from a community-based
prospective study of men and women for a median of
8.6 years, we demonstrated that the LAP was
independently associated with an increased risk of inci-
dent CVD among women and that the magnitude of
this risk was not significantly higher than those con-
ferred by BMI, WHpR, or WHtR. Among men, after
controlling common CVD risk factors, we observed that
LAP was not associated with any significant increased
risk of incident CVD. The only exception observed was
among a subgroup of men who were assigned to the life
style modification interventions. In this sub-group a 1-
SD increment in naturally logarithmatically transformed
LAP conveyed a 58% increased CVD risk. Among men
the magnitude of risk conferred by WHpR exceeded
that of LAP. No associations were observed between the
LAP and increased risk of all-cause mortality in men or
women.
As a component of a multivariate predictive model for
incident CVD, the LAP, BMI, WHpR, and WHtR had
the same performance with respect to the discrimination
Figure 1 Kaplan-Meier curves for incident CVD across LAP
quartiles in men with global CVD risk less than 20%.
Figure 2 Kaplan-Meier curves for incident CVD across LAP
quartiles in men with global CVD risk 20% or more.
P for trend <0.001
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Figure 3 Kaplan-Meier curves for incident CVD across LAP
quartiles in women with global CVD risk less than 20%.
Figure 4 Kaplan-Meier curves for incident CVD across LAP
quartiles in women with global CVD risk 20% or more.
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Page 8 of 13capacity and the calibration. Trade-offs between bias
and variance (AIC and BIC), due to incorporating LAP
into multivariate predictive models was similar to those
due to BMI, WHpR, or WHtR.
Some studies recently compared different anthropo-
metric measures in terms of their ability to predict
CVD. They observed that measures of central and over-
all adiposity predicted CVD to a similar degree except
for slight superiority for WHpR [49-52].
Nearly one-third of the population in the industria-
lized world are currently affected by obesity [53].
Whether obesity exerts independent and direct effects
on CVD beyond its strong association with established
clinical risk factors remains controversial [54]. Currently
used risk functions for the prediction of coronary events
in the general population do not include measures of
excess body weight because it is considered to affect
risk indirectly through more proximal physiological and
metabolic factors such as blood pressure, lipid levels,
and diabetes [55]. Traditionally, anthropometric mea-
sures such as BMI or WC have been used to quantify
adiposity. Results from the present study support other
studies that have found that “obesity predicts risk of
CVD incidence beyond the established clinical condi-
tions” [54]. Abdominal visceral adipose tissue (VAT) has
been highlighted as unique, pathogenic fat depots
[56,57]. VAT is hypothesized to have a systemic effect
on atherosclerosis. LAP, has been reported to offer an
inexpensive and non invasive tool to estimate total body
lipid accumulation in comparison with sophisticated
imaging methods for estimating the lipid burden or
uptake in isolated tissues [21]. The fact that, unlike
LAP, the MetS components are not used as continuous
variables makes these screening tools less than ideal for
the optimal diagnosis of the cardio-metabolic risk [8]. It
is commonly believed that only new calculators
Figure 5 Kaplan-Meier curves for all-cause mortality across LAP
quartiles in men with global CVD risk less than 20%.
Figure 6 Kaplan-Meier curves for all-cause mortality across LAP
quartiles in men with global CVD risk 20% or more.
Figure 7 Kaplan-Meier curves for all-cause mortality across LAP
quartiles in women with global CVD risk less than 20%.
Figure 8 Kaplan-Meier curves for all-cause mortality across LAP
quartiles in women with global CVD risk 20% or more.
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Page 9 of 13providing a continuous score could address this issue
[58] and LAP has been developed on such a back-
ground. We observed, however, that if LAP is to be
used for predicting CVD, it might not be superior to
WHtR or WHpR.
Our results confirm the association of LAP with CVD
risk factors. LAP increased risk of incident CVD among
women. The same finding has been previously reported
[59]. LAP predicted CVD risk only among men who
were assigned to the lifestyle modification interventions.
LAP may not predict CVD risk among men who are
already at increased risk for CVD. We failed to demon-
strate any association with increased risk of all-cause
mortality due to LAP. In fact, after adjustment with
CVD risk factors, LAP came to be inversely associated
with risk of all-cause mortality. This association, how-
ever, was statistically significant among men (HR 0.74,
95% CIs 0.61-0.90) but not among women (HRs 0.94
95% CIs 0.74-1.20). This negative confounding would
not be underappreciated. No clear-cut explanation,
though, is readily available and confirmation in an inde-
pendent study is required before this surprising observa-
tion could be understood. There is, to our knowledge,
only one other study (PreCIS data base study), in which
LAP has been found to be independently associated
with increased mortality in both sexes. In the PreCIS
Table 5 Contribution of LAP to the risk of CVD and all-cause mortality, independent of common CVD risk factors
Men Women
HR* (95% CIs) P-value HR* (95% CIs) P-value
CVD Global CVD risk
† <20% 1.07 (0.80-1.42) 0.643 1.46 (1.05-2.03) 0.025
Global CVD risk
† ≥20% 1.09 (0.90-1.32) 0.374 1.20 (0.75-1.92) 0.440
All-cause mortality Global CVD risk
† <20% 0.75 (0.52-1.08) 0.128 0.74 (0.48-1.15) 0.183
Global CVD risk
† ≥20% 0.80 (0.62-1.01) 0.064 1.17 (0.54-2.57) 0.688
CVD Assigned to the intervention 1.58 (1.11-2.26) 0.011 1.43 (0.89-2.29) 0.143
Not assigned to the intervention 1.01 (0.82-0.1.25) 0.896 1.33 (0.90-1.96) 0.148
All-cause mortality Assigned to the intervention 0.71 (0.49-1.02) 0.061 1.16 (0.62-2.15) 0.641
Not assigned to the intervention 0.77 (0.61-0.98) 0.034 0.73 (0.44-1.20) 0.214
* For one SD increment in each continuous predictor, obtained from multivariate Cox proportional hazards regression model adjusted for age, smoking, systolic
blood pressure, family history of premature CVD, diabetes, antihypertensive drug usage, HDL and non-HDL cholesterol, FPG, and 2h-PCPG , plus the TLGS
intervention measures.
†calculated using “the Framingham general CVD prediction algorithm”.( D ’Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB:
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. Circulation 2008, 117:743-753)
CVD, cardiovascular disease; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; Ln,
naturally logarithmically transformed; 2h-PCPG, 2-hour post-challenge plasma glucose;
Table 6 Predictive accuracy of the LAP as compared with those of BMI, WHpR, and WHtR
Factor HR* (95% CIs) Wald Χ
2 (P value)
† AIC BIC Discrimination
¥ Calibration
¶
Male
LAP 1.06 (0.89-1.26) - 3134 3204 0.785 (0.756-0.813) 21.6 (0.010)
BMI 1.12 (0.94-1.33) 0.51 (0.474) 3133 3203 0.785 (0.759-0.811) 18.4 (0.031)
WHpR 1.25 (1.06-1.47) 4.62 (0.032) 3128 3198 0.788 (0.762-0.814) 18.0 (0.035)
WHtR 1.20 (1.00-1.43) 2.69 (0.101) 3131 3201 0.787 (0.759-0.814) 15.1 (0.088)
Female
LAP 1.41 (1.02-1.96) - 1876 1947 0.846 (0.818-0.875) 12.2 (0.201)
BMI 1.15 (0.97-1.37) 0.81 (0.367) 1878 1951 0.847 (0.825-0.868) 12.8 (0.170)
WHpR 1.35 (1.10-1.65) 0.13 (0.718) 1872 1945 0.848 (0.820-0.876) 11.9 (0.218)
WHtR 1.30 (1.08-1.57) 0.17 (0.680) 1873 1946 0.849 (0.825-0.873) 12.6 (0.180)
* Hazard ratios for one SD increment in each anthropometric variable and one SD increment in log LAP level, obtained from multivariate Cox proportional hazard
regression model adjusted for age, smoking, systolic blood pressure, family history of premature CVD, diabetes, smoking, antihypertensive drug usage, HDL and
non-HDL cholesterol, FPG, and 2h-PCPG , plus the TLGS intervention measures
† Wald tests Χ
2 (P value) of the linear hypotheses concerning the Cox regression models coefficients (paired homogeneity test) were performed to test the null
hypotheses that the hazard ratios (effect size) for LAP were equal to those for BMI, WHpR, or WHtR.
¥ Assessed with C statistic (95% CIs)
¶ Assessed with Hosmer-Lemeshow Χ
2 (P value)
Abbreviations: AIC: Akaike information criteria; BIC: Bayesian information criteria; BMI: body mass index; LAP: lipid accumulation product; WHpR: waist-to-hip ratio;
WHtR: waist-to-height ratio;
Standard deviations: Men ® LAP (mmol.cm) (naturally logarithmically-transformed),1.15; BMI (kg.m
-2), 3.9; WHpR (%)7.0;WHtR 6.5 (%)
Standard deviations: Women® LAP (mmol.cm) (naturally logarithmically-transformed), 0.81; BMI (kg.m
-2), 4.7; WHpR (%)8.3;WHtR 8.1 (%)
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Page 10 of 13population, LAP was reported to be associated with all-
cause mortality and the association was stronger among
women than among men [59]. The proportion of CVD
deaths in all deaths can explain the discrepancy, since
only 36.6% of deaths in the TLGS were attributable to
the CVD while the PreCIS population is known to be at
increased risk of mortality from CVD. As compared to
t h eT L G S ,t h eP r e C I Sp o p u l a t i o nw e r eo l d e r( m e a na g e
55 years) and at a greater risk of CVD; the prevalence of
hypertension, diabetes, family history of CVD, and CVD
were 65, 19, 42, and 59% respectively [59]. The corre-
sponding figures in the TLGS population were 24, 17.1,
6.2, and 10.3%, respectively. Differences in the baseline
LAP from one cohort to another may also account for
different findings. Other possible explanations may be
the covariance of obesity with other CVD risk factors,
unmeasured confounders, or misclassification bias from
use of surrogate markers of obesity [53,56].
WC was not associated with increased all-cause mor-
tality among the TLGS’ m e no rw o m e n .I np r e v i o u s
studies showing the association between WC and mor-
tality, the association was stronger for CVD mortality
than overall mortality [59]. Among men, we observed
TG to be inversely associated with all-cause mortality
(HR 0.75, 95% CIs 0.56-1.00); WC showed no associa-
tion with mortality (HR 0.90, 95% CIs 0.72-1.12). Dif-
ference in methods used to measure WC in different
studies could at least partly describe the difference in
the results obtained. The consequences of elevated
TGs are controversial and the benefit of reducing
these levels is yet to be clarified. Inverse or lack of
association between TGs levels and all-cause mortality
has previously been reported [60,61]. Men have been
shown to be resistive to hazards of adiposity; and
mild-grade central obesity has been reported to be
protective [51]. Lower TGs levels resulting from mal-
nourishment, combined with lower WC due to recent
weight loss related to chronic illness might have biased
our findings. In developing countries mortalities are
still more likely to be due to chronic inflammations,
undernourishment, or cancers than CVDs, and there-
fore, may be less likely to be associated with CVD risk
factors including LAP [62,63]. Some investigators
argued that introduction of both HDL-C and TGs as
independent covariates in a model is inappropriate
owing to multicollinearity and an intimate correlation
between these variables in lipid metabolism [64]. How-
ever, even after we excluded HDL-C from analyses the
results remained essentially unchanged (data not
shown).
Strength of the present study lies in its prospective
nature, the use of a large population-based-cohort of
both sexes, accurate and valid data on risk factors at
baseline, continuous surveillance of mortality and CVD
events based on standard criteria.
Some limitations to our study merit mentioning. First,
in this study, no data was available about TGs lowering
drugs. Second, the small number of incident events pre-
cluded stratification of analyses by age. Third, sub-group
samples might not have enough statistical power to
detect effects. Finally, the population studied was of Per-
sian ancestry, our results, thus, cannot be readily extra-
polated to other populations.
Conclusion
We demonstrated that the LAP was independently asso-
ciated with an increased risk of incident CVD among
women and that the magnitude of this risk due to LAP
was not significantly higher than those due to BMI,
WHpR, or WHtR. However, among men, after control-
ling common CVD risk factors, we observed that LAP
was not associated with any significant increased risk of
incident CVD, except for those assigned to the lifestyle
modification interventions. Among men, the magnitude
of risk conferred by WHpR exceeded that conferred by
LAP. No association was observed between the LAP and
increased risk of all-cause mortality in women. Among
men, LAP was inversely associated with all-cause mor-
tality. If LAP is to be used for predicting CVD, it might
not be superior to WHtR or WHpR.
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